Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

Eli Lilly's ( LLY) weight-loss drug, Mounjaro, has become the best-selling medication in India by value as of October, ...

By volume, Augmentin was way higher than Mounjaro with 5,784 units sold during October, compared to just 85 units sale of ...

Eli Lilly's Mounjaro became India's highest-selling drug in October with ₹100 crore sales. The anti-obesity treatment now ...

Eli Lilly's blockbuster obesity ​drug Mounjaro became India's ‌top-selling drug by value for the ‌month of October with sales ...

Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.

Eli Lilly's Mounjaro tops India's drug sales in October, surpassing GSK's Augmentin with ₹100 crore in revenue.

Eli Lilly's weight-loss therapy Mounjaro became India's top-selling drug by value in October, data showed on Friday, ...

The anti-obesity drug registered sales of ₹100 crore in October, unseating the previous best-selling antibiotic Augmentin, ...

Eli Lilly's Mounjaro recorded Rs 100 crore in October sales, overtaking long-time market leaders as cumulative revenue ...

Eli Lilly recorded ₹1 billion in Mounjaro sales in October, compared to Augmentin’s ₹800 million ・Since its March 2025 launch ...

Donald Trump has signed deals with the pharma giants Novo Nordisk and Eli Lilly to lower the prices of antiobesity drugs and ...